Literature DB >> 16598880

Xaliproden lessens oxaliplatin-mediated neuropathy.

Ed Susman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16598880     DOI： 10.1016/s1470-2045(06)70639-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  8 in total

1.  Systemic treatment with a 5HT1a agonist induces anti-oxidant protection and preserves the retina from mitochondrial oxidative stress.

Authors:  Manas R Biswal; Chulbul M Ahmed; Cristhian J Ildefonso; Pingyang Han; Hong Li; Hiral Jivanji; Haoyu Mao; Alfred S Lewin
Journal:  Exp Eye Res       Date:  2015-08-25       Impact factor: 3.467

2.  Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study.

Authors:  Stefan von Delius; Florian Eckel; Stefan Wagenpfeil; Martina Mayr; Konrad Stock; Frank Kullmann; Florian Obermeier; Johannes Erdmann; Renate Schmelz; Stefan Quasthoff; Helmuth Adelsberger; Rainer Bredenkamp; Roland M Schmid; Christian Lersch
Journal:  Invest New Drugs       Date:  2006-09-13       Impact factor: 3.850

3.  The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen.

Authors:  Masanori Nishioka; Mitsuo Shimada; Nobuhiro Kurita; Takashi Iwata; Shinya Morimoto; Kozo Yoshikawa; Jun Higashijima; Tomohiko Miyatani; Toru Kono
Journal:  Int J Clin Oncol       Date:  2011-01-22       Impact factor: 3.402

Review 4.  Platinum-induced neurotoxicity and preventive strategies: past, present, and future.

Authors:  Abolfazl Avan; Tjeerd J Postma; Cecilia Ceresa; Amir Avan; Guido Cavaletti; Elisa Giovannetti; Godefridus J Peters
Journal:  Oncologist       Date:  2015-03-12

Review 5.  Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain.

Authors:  Thierry Bordet; Rebecca M Pruss
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

Review 6.  Platinum neurotoxicity pharmacogenetics.

Authors:  Sarah R McWhinney; Richard M Goldberg; Howard L McLeod
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

7.  5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.

Authors:  J-C Martel; M-B Assié; L Bardin; R Depoortère; D Cussac; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

8.  Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity.

Authors:  Sarah McWhinney-Glass; Stacey J Winham; Daniel L Hertz; Jane Yen Revollo; Jim Paul; Yijing He; Robert Brown; Alison A Motsinger-Reif; Howard L McLeod
Journal:  Clin Cancer Res       Date:  2013-08-20       Impact factor: 12.531
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.